MetaVision-SPR: a 96-well chromatic Meta-SPR imaging platform for tumor biomarker quantification and apparent kinetic prescreening.

We report MetaVision-SPR, a 96-well chromatic metasurface plasmon resonance (Meta-SPR) imaging platform for serum biomarker quantification and apparent kinetic analysis. The system integrates a nanocup-array Meta-SPR chip, light-emitting diode (LED) illumination, an industrial camera, and computational correction including automated well recognition, sucrose-reference-based optical flat-field correction, and Δ(R-G) chromatic readout. Spectral simulation and optical response matching identified the 20/75/25 nm Ti/Ag/Au structure and Δ(R-G) signal as the optimal chip-readout combination for quantitative imaging. Flat-field correction reduced inter-well variation in a Protein A/immunoglobulin G (IgG) assay from 26.74% to 6.74%, while programmable shaking improved mass transport in the open-well format. Using gold nanoparticle (AuNP)-enhanced sandwich assays, the platform enabled sensitive detection of alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) with limits of detection (LoDs) of 5.0 pg/mL for AFP, 10.0 pg/mL for CEA and 0.49 U/mL for CA19-9. Clinical serum measurements showed reference-method consistency with hospital electrochemiluminescence immunoassay (ECLIA) and commercial enzyme-linked immunosorbent assay (ELISA) results. In addition, the system supported real-time measurement of binding curves for antibody-drug conjugate and lipopolysaccharide-related interactions, yielding apparent kinetic parameters suitable for high-throughput screening. These results support MetaVision-SPR as a low-hardware-cost 96-well chromatic Meta-SPR workflow for serum biomarker measurement and apparent interaction ranking.